Please assess the completion status of the following clinical trial:

Trial Title: Pirfenidone, an Antifibrotic and Antiinflammatory Drug

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with established advanced liver disease caused by hepatitis C virus (HCV) chronic infection defined by a positive test for anti-HCV antibodies and detectable serum HCV RNA (Amplicor HCV 2.0 polymerase chain reaction (PCR) assay).~* Sign an informed consent form to allow the collection of liver biopsies before and after treatment.~* No antifibrotic, antiviral or immunosuppressive drugs for at least 6 months before starting pirfenidone therapy.~* No alcohol intake for at least 6 months before nor during Pirfenidone (PFD) treatment.~Exclusion Criteria:~* Patients with clinical contraindications to hepatic biopsy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Pirfenidone (Type: EXPERIMENTAL): Pirfenidone 400 mg capsules, orally administered thrice daily to yield a daily dose of 1200 mg during two years.
- Matched equivalent placebo (Type: PLACEBO_COMPARATOR): Matched equivalent placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).